CXCL13 and neoplasm: Significantly, CXCL13 levels were diminished in both serum and RFA-treated, neutrophil-depleted tumors, suggesting that a decrease in this chemokine might be linked to mitigated tumor growth and emphasizing the significance of neutrophils in the systemic anti-tumor response following RFA [42].